Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 2 Trial of IMC-3G3 Plus Liposomal Doxorubicin in Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer
2009-009035-30Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of olaratumab in ovarian cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Aug 2009; status: completed.
02
Drugs
olaratumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2009-009035-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009035-30.